MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Latest Information Update: 18 Jun 2024
At a glance
- Drugs Elranatamab (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms Elemmental-3; MagnetisMM-3
- Sponsors Pfizer
- 14 Jun 2024 According to a Pfizer media release, the company announced detailed overall survival (OS) results which will be presented during a poster session (#932) at the European Hematology Association (EHA) Hybrid Congress in Madrid, Spain, from June 13-16.
- 26 Mar 2024 According to a Pfizer media release, based on results from MagnetisMM-3 and MagnetisMM-2 study the company has obtained manufacturing and marketing approval in Japan for Elrefio subcutaneous injection 44mg, 76mg in Japan for patients with relapsed or refractory multiple myeloma.
- 01 Mar 2024 Planned End Date changed from 6 Apr 2024 to 31 Dec 2025.